fenofibrate 150 MG Oral Capsule [Lipofen]

Verify with CMS →

fenofibrate

RxCUI: 702055

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0.2%
Plan Coverage
10
Plans Covering
T4
Avg Tier
0%
Prior Auth Required

What the CMS Formulary Data Shows for fenofibrate 150 MG Oral Capsule [Lipofen]

Per the CMS 2026 Part D formulary file, fenofibrate 150 MG Oral Capsule [Lipofen] (RxNorm concept RXCUI 702055, generic name fenofibrate) appears on 1 distinct formulary file spanning 10 Medicare Part D plan offerings - 0.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 4 to Tier 4, with a cross-plan average of Tier 4.

Real-world access to fenofibrate 150 MG Oral Capsule [Lipofen] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 500,170 Part D beneficiaries filled fenofibrate 150 MG Oral Capsule [Lipofen] in 2023, with total plan-and-beneficiary spending of $74,983,711 and an average per-beneficiary annual cost of $149.92. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry fenofibrate 150 MG Oral Capsule [Lipofen] today.

Coverage Details

Formularies covering
1
Plans covering
10
Coverage rate
0.2%
Tier range
Tier 4, Non-Preferred
Average tier
Tier 4, Non-Preferred

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
500,170
Total spending
$74,983,711
Avg per beneficiary
$149.92

Tier Distribution Across Plans

10 plans
Tier 4, Non-Preferred

Standalone Drug Plans (PDP) Covering fenofibrate 150 MG Oral Capsule [Lipofen]

2 standalone prescription drug plans include this drug.

Plan Insurer Tier PA ST Premium States
Blue Rx PDP Complete (PDP) HM HEALTH INSURANCE COMPANY T4 No No $164.80 -
Blue Rx PDP Plus (PDP) HM HEALTH INSURANCE COMPANY T4 No No $193.20 -

Medicare Advantage Plans (MA-PD) Covering fenofibrate 150 MG Oral Capsule [Lipofen]

8 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Security Blue HMO-POS Standard (HMO-POS) HIGHMARK CHOICE COMPANY T4 No $51.80 PA
Freedom Blue PPO Select (PPO) HIGHMARK SENIOR HEALTH COMPANY T4 No $95.70 PA
Security Blue HMO-POS Deluxe (HMO-POS) HIGHMARK CHOICE COMPANY T4 No $95.90 PA
Freedom Blue PPO Standard (PPO) HIGHMARK SENIOR HEALTH COMPANY T4 No $98.20 PA
Freedom Blue PPO Select (PPO) HIGHMARK SENIOR HEALTH COMPANY T4 No $115.70 PA
Freedom Blue PPO Deluxe (PPO) HIGHMARK SENIOR HEALTH COMPANY T4 No $122.40 PA
Freedom Blue PPO Classic (PPO) HIGHMARK SENIOR HEALTH COMPANY T4 No $140.90 PA
Freedom Blue PPO Classic (PPO) HIGHMARK SENIOR HEALTH COMPANY T4 No $145.40 PA

Frequently Asked Questions

Is fenofibrate 150 MG Oral Capsule [Lipofen] covered by Medicare Part D?

Yes, fenofibrate 150 MG Oral Capsule [Lipofen] is covered by 10 Medicare Part D plans (0.2% of all Part D formularies).

What tier is fenofibrate 150 MG Oral Capsule [Lipofen] on Medicare Part D plans?

fenofibrate 150 MG Oral Capsule [Lipofen] averages Tier 4 across Part D plans, ranging from Tier 4 to Tier 4.

Does fenofibrate 150 MG Oral Capsule [Lipofen] require prior authorization?

0% of Part D formularies require prior authorization for fenofibrate 150 MG Oral Capsule [Lipofen]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on fenofibrate 150 MG Oral Capsule [Lipofen]?

In 2023, total Medicare Part D spending on fenofibrate 150 MG Oral Capsule [Lipofen] was $74,983,711, covering 500,170 beneficiaries. The average spend per beneficiary was $149.92.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial